Skip to main content

Hillhouse Investment Management, Ltd.'s Form 4 filing

ArriVent BioPharma, Inc. (AVBP) · filed Feb 1, 2024

Accession no.
0000902664-24-000903
Filed
Feb 1, 2024, 4:47 PM ET
Trade date
Jan 30, 2024
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market purchases total $10.0M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Hillhouse Investment Management, Ltd.CIK 000151058910% Owner
HHLR Advisors, Ltd.CIK 000176230410% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 30, 2024Common StockCConversionAcquired+3,616,041––3,616,041Indirect
Jan 30, 2024Common StockCConversionAcquired+313,076––3,929,117Indirect
Jan 30, 2024Common StockPPurchaseAcquired+555,555$18.00+$9,999,9904,484,672Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 30, 2024Common StockCConversionDisposed−3,616,041$0.00$00Indirect
Jan 30, 2024Common StockCConversionDisposed−313,076$0.00$00Indirect

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)